Table 7.
Primary outcome in Randomized Controlled Trials in AOMS.
| Reduction in ARR | Relative Risk Reduction to Placebo | Reduction in Sustained Disability | Reduction in MRI New T2 Lesions | Reduction in New Gad Enhancing Lesions | |
|---|---|---|---|---|---|
| Alemtuzumab | Not tested vs placebo | ||||
| Dimethyl fumarate [41] vs. placebo | 53,48% | 44% | 34%, 38% | 85% | 90% |
| Fingolimod [42] | See Table 6 for POMS data | 23% | |||
| Natalizumab | 68% | 42% | 83% | ||
| Daclizumab (removed from the market willingly by Biogen) | 45% compared with IFN β 1a | 45–54% | 54% new or new enlarging T2 | ||
| Ocrelizumab [43,44] | 44, 46% compared with IFN β 1a | 46–47% | Slow disability in PPMS | ||
| Teriflunomide [45] | 31% | 29% | 69% against placebo | Free from gad lesions 89% compared with placebo | |
| Cladribine [46] | 66% | Slowed 3-month disability 33% | 86% |